Últimas noticias sobre Psyence Biomedical (NASDAQ:PBM) Bolsa

Psyence Biomedical

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical Ltd

PACIFIC BAY MINERALS LTD by Pacific Bay Minerals Ltd.

Pacific Bay Minerals Ltd

PACIFIC BOOKER MINERALS by Pacific Booker Minerals Inc.

Pacific Booker Minerals Inc

PGIM US Large-Cap Buffer 12 ETF - January PGIM US Large-Cap Buffer 20 ETF - March

PT BUMI RESOURCES TBK by PT Bumi Resources TBK

PT Bumi Resources Tbk

PT BUMI RESTBK UNSP/ADR by PT Bumi Resources TBK

SHL Telemedicine Ltd PGIM US Large-Cap Buffer 20 ETF - May

Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) ("Psyence Biomed" or the "Company"), a developer of psilocybin-based therapeutics, today provided an update on its previously announced proposed acquisition of Clairvoyant Therapeutics, Inc. Following the completion of necessary due diligence and other pre-closing activities specified in the conditional binding term sheet that was announced on September 9, 2024, Psyence Biomed has decided not to proceed with the acquisition at this time.
Psyence Biomed continues to advance its recently initiated Phase IIb clinical trial of nature derived psilocybin in conjunction with psychotherapy as a potential treatment for Adjustment Disorder following a life-limiting cancer diagnosis in Palliative Care. The first patient is expected to be randomized into the study this quarter, and topline data from the study is anticipated in the second half of 2025.
 &nbsp;

News

Contracts

Psyence Biomed Announces It Has Decided Not To Proceed With The Acquisition Of Clairvoyant At This Time

Asset Sales

Psyence Group Enters Agreement To Sell 11.13% Stake In Psylabs

Per the terms of the Proposed Acquisition, Psyence Biomed will issue to Psyence Group shares of its common stock valued at&nbsp;$1.1 million&nbsp;dollars, at a price of&nbsp;$0.55&nbsp;per share, in exchange for Psyence Group&#39;s&nbsp;11.13%&nbsp;stake in PsyLabs.

Psyence Biomedical Enters Agreement With Psyence Group For Acquisition Of 11.13% Stake In Privately-held PsyLabs For About $1.1M

Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>), a biotechnology company focused on creating natural psychedelic-based solutions to address mental health challenges, has issued an <a href="https://www.globenewswire.com/news-release/2024/09/16/2946540/0/en/Psyence-Biomed-Issues-Shareholder-Update-Recapping-Recent-Progress-and-Previewing-Key-Upcoming-Data-Milestones.html">update</a> to shareholders, highlighting significant recent developments and upcoming milestones. 
The company has initiated a <a href="https://www.benzinga.com/markets/cannabis/24/09/40783399/psyence-biomed-launches-first-trial-site-in-australia-for-phase-iib-psilocybin-study-in-palliati">Phase IIb clinical trial in Australia</a> to evaluate psilocybin-assisted therapy for Adjustment Disorder in palliative care. Results are expected in late 2025, with hopes to advance to a Phase III trial thereafter. Psyence also strengthened its clinical supply chain by partnering with Optimi Health (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OPTHF#OTC">OPTHF</a>) for GMP psilocybin extracts.
In addition to its palliative care program, Psyence expanded its pipeline into Substance Use Disorders, specifically Alcohol Use Disorder (AUD), through an exclusive licensing agreement with Psylabs. 
The company also announced the acquisition of Clairvoyant, a synthetic psilocybin drug developer, enhancing Psyence's AUD development efforts with data expected in early 2025.
These initiatives position Psyence for two critical data readouts in 2025, potentially paving the way for commercial success. Psyence also emphasized its strengthened financial position to support these ventures. CEO Dr. Neil Maresky expressed optimism about Psyence&#8217;s progress in developing <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-based therapies</a> for mental health.
Cover image made with AI

Cannabis

Psychedelics

Press Releases

OPTHF

Psychedelic Biotech Psyence Grows Pipeline With Trials And Psilocybin Drug Developer Acquisition

<a href="https://www.globenewswire.com/en/news-release/2024/09/16/2946746/0/en/Psyence-Group-s-NASDAQ-Listed-Associate-Psyence-Biomedical-Announces-Initiation-of-First-Trial-Site-in-Australia-for-its-Phase-IIb-Study-of-Nature-Derived-Psilocybin-as-a-Potential.html" title="https://www.globenewswire.com/en/news-release/2024/09/16/2946746/0/en/Psyence-Group-s-NASDAQ-Listed-Associate-Psyence-Biomedical-Announces-Initiation-of-First-Trial-Site-in-Australia-for-its-Phase-IIb-Study-of-Nature-Derived-Psilocybin-as-a-Potential.html">https://www.globenewswire.com/en/news-release/2024/09/16/2946746/0/en/Psyence-Group-s-NASDAQ-Listed-Associate-Psyence-Biomedical-Announces-Initiation-of-First-Trial-Site-in-Australia-for-its-Phase-IIb-Study-of-Nature-Derived-Psilocybin-as-a-Potential.html</a>

Psyence Biomedical Announces Initiation Of First Trial Site In Australia For Phase IIb Study Of Nature Derived Psilocybin As Potential Treatment For Adjustment Disorder In Palliative Care

Shares of Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) rose sharply in today's pre-market trading after the company entered into debt-for-equity exchange agreements and <a href="https://www.benzinga.com/quote/XCUR/news">regained Nasdaq compliance.</a>
Exicure shares jumped 49.3% to $2.39 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>NuCana plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) gained 94.4% to $4.94 in pre-market trading. NuCana presented final data from Phase 2 Nutide:701 study at ESMO Congress on NUC-7738 in combination with pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy.</li>
<li>Dermata Therapeutics, Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) rose 73.4% to $2.74 in today's pre-market trading after gaining around 7% on Tuesday.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) gained 53.1% to $2.68 in the pre-market trading session. Agape ATP shares jumped over 20% on Friday after the company announced it entered into a strategic collaboration with Xiamen Photons Solar Technology that focusing on developing solar photovoltaic mounting systems in ASEAN countries.</li>
<li>Tenon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) gained 22.1% to $9.22 in pre-market trading after jumping around 72% on Friday. The company announced the pricing of a $4.5 million public offering of 1.22 million shares and warrants.</li>
<li>iTeos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) rose 20.1% to $20.05 in pre-market trading. iTeos Therapeutics announced follow-up interim data from GALAXIES Lung-201 Phase 2 platform study sponsored by GSK, for Belrestotug+Dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer.</li>
<li>IO Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) rose 18.2% to $0.8874 in pre-market trading. IO Biotech announced data from Phase 2 Basket trial of IO102-IO103, therapeutic cancer vaccine candidate, in combination with Merck&#8217;s Keytruda at the 2024 ESMO Congress.</li>
<li>Yunji Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YJ#NASDAQ">YJ</a>) gained 14.3% to $2.48 in pre-market trading after gaining 12% on Friday.</li>
<li>Adagene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAG#NASDAQ">ADAG</a>) shares rose 13.7% to $ 3.97 in pre-market trading. Adagene announced new ADG126 clinical data from ongoing Phase 1b/2 trial of SAFEbody Plus Keytruda Combo Presented at the ESMO Congress.</li>
<li>Entero Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) gained 9% to $0.38 in pre-market trading after gaining around 6% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Rafael Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) fell 40.1% to $1.00 in pre-market trading after gaining 9% on Friday.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares dipped 21.8% to $4.65 in pre-market trading after surging 143% on Friday.</li>
<li>Presidio Property Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQFT#NASDAQ">SQFT</a>) fell 20.4% to $0.55 in pre-market trading.</li>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares fell 16.7% to $0.13 in pre-market trading. Psyence Biomedical announced the receipt of staff delisting determination from Nasdaq.</li>
<li>Edgio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGIO#NASDAQ">EGIO</a>) shares declined 14.7% to $1.33 in pre-market trading after dipping 27% on Friday.</li>
<li>Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 11.6% to $0.48 in pre-market trading after dipping around 67% on Friday.</li>
<li>Protagenic Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares fell 11.4% to $0.7001 in pre-market trading after declining 9% on Friday.</li>
<li>Purple Biotech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) shares declined 11.2% to $0.3438 in pre-market trading after gaining 7% on Friday.</li>
<li>LeddarTech Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) fell 9.4% to $0.4001 in today's pre-market trading.</li>
<li>Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) declined 8.2% to $24.60 in pre-market trading after gaining around 5% on Friday.</li>
</ul>
<a href="https://www.benzinga.com/markets/24/09/40860420/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics">Now Read This: </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40860420/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics">Jim Cramer: &#8216;Hold On&#8217; To Builders FirstSource, &#8216;Here&#8217;s The Problem&#8217; With Viking Therapeutics</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADAG

ATPC

DRMA

EGIO

ENTO

IOBT

ITOS

LDTC

NCNA

PPBT

PTIX

SQFT

TNON

XCUR

Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket

Psyence Biomedical Receives Nasdaq Delisting Determination; Company Has Not Regained Compliance

Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) announced a major milestone on Monday with the initiation of the first clinical trial site in Australia for its Phase IIb study on nature-derived <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> as a potential treatment for Adjustment Disorder in patients receiving palliative care. This development marks a key step toward advancing <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-based treatments</a> in the healthcare industry.
The trial, conducted in partnership with Fluence, a leader in psychedelic therapy research, and iNGENū CRO Pty Ltd, a renowned Australian clinical research organization, aims to explore the efficacy of Psyence's naturally sourced psilocybin drug, <a href="https://www.benzinga.com/markets/cannabis/23/03/31444645/psychedelic-research-expands-in-australia-with-palliative-care-partnership-new-mdma-analog-portf">PEX010</a>. As the company <a href="https://www.globenewswire.com/news-release/2024/09/09/2942714/0/en/Psyence-Biomed-Announces-Initiation-of-First-Trial-Site-in-Australia-for-its-Phase-IIb-Study-of-Nature-Derived-Psilocybin-as-a-Potential-Treatment-for-Adjustment-Disorder-in-Pallia.html">stated</a>, patient screening is set to begin immediately, with the first subject expected to be randomized in October.
<h3 class="wp-block-heading">A Critical Advancement For Psychedelic Therapeutics</h3>
Dr. Clive Ward-Able, medical director of Psyence Biomedical, expressed enthusiasm about the trial's progression. &#8220;The imminent activation of the first trial site and patient screening for this trial represents a significant milestone for our company and a positive step forward for the advancement of psychedelic-based therapeutics generally,&#8221; he said. He emphasized that data from the study, expected in the second half of 2025, could pave the way for a pivotal Phase III clinical program.
The study will investigate the effects of psilocybin on patients suffering from Adjustment Disorder, particularly those dealing with life-limiting cancer diagnoses. The randomized, double-blind, placebo-controlled trial will evaluate two therapeutic doses of psilocybin (10mg and 25mg) against an active low-dose comparator (1mg) in conjunction with psychotherapy, enrolling 87 patients.
<h3 class="wp-block-heading">Promising Partnerships Driving Innovation</h3>
Veronika Simic, senior clinical project manager at iNGENū, highlighted the potential of psilocybin in addressing unmet mental health needs. &#8220;We believe psilocybin holds great promise as a treatment for a broad range of mental health conditions,&#8221; Simic stated. She also reaffirmed iNGENū's commitment to efficiently advancing the study in collaboration with Psyence Biomedical.
The <a href="https://www.benzinga.com/news/24/07/39966103/why-psyence-biomedical-pbm-stock-is-skyrocketing">export of PEX010 to Australia</a> earlier this year was a crucial preparatory step, and the trial site's activation signals significant progress toward exploring the therapeutic potential of naturally derived psilocybin.
Cover image made with AI

Psyence Biomed Launches First Trial Site In Australia For Phase IIb Psilocybin Study In Palliative Care

General

Psyence Biomedical shares are trading higher after the company announced it entered into a conditional binding term sheet to acquire 100% of the shareholdings of Clairvoyant Therapeutics.

As consideration for the Proposed Acquisition, Psyence Biomed will issue $500,000 of the Company&#39;s common shares upon closing to Clairvoyant&#39;s disposing shareholders, followed by potentially up to two share-based payments of $250,000 each (payable in cash or common shares, at the Company&#39;s election) upon the achievement of pre-specified milestones by December 2026.
In addition, Psyence Biomed will advance funds in tranches of up to $1.80 million in aggregate to Clairvoyant in order to settle its liabilities, which consist primarily of clinical trial costs.

Psyence Biomedical Enters Conditional Binding Term Sheet For Proposed Acquisition Of Privately-held Clairvoyant Therapeutics

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 0.2% on Wednesday.
The Dow traded down 0.08% to 40,906.17 while the NASDAQ rose 0.21% to 17,172.66. The S&amp;P 500 also fell, dropping, 0.03% to 5,527.51.
Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40706790/top-3-consumer-stocks-that-could-blast-off-this-quarter"> Top 3 Consumer Stocks That Could Blast Off This Quarter</a>
Leading and Lagging Sectors Utilities shares climbed by 0.6% on Wednesday.
In trading on Wednesday, energy shares fell by 0.9%.
Top Headline
Shares of Dollar Tree, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) dipped over 21% on Wednesday after the company reported worse-than-expected second-quarter 2024 earnings.
The discount variety stores chain reported an adjusted EPS of 67 cents, missing the consensus of $1.04, and down 26.4% year over year. The company reported sales of $7.38 billion, up marginally by 0.07%, missing the consensus of $7.5 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) shares shot up 43% to $4.8986.</li>
<li>Shares of Atara Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) got a boost, surging 32% to $9.00. The company announced a $36 million registered direct offering of 758,900 shares at $8.25 per share.</li>
<li>WiSA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WISA#NASDAQ">WISA</a>) shares were also up, gaining 69% to $2.30 after the company announced that it executed a definitive asset purchase agreement to purchase the Datavault intellectual property and information technology assets of privately held Data Vault Holdings for $210 million.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Athira Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) shares dropped 78% to $0.6361 after the company released topline results from its Phase 2/3 LIFT-AD clinical trial of fosgonimeton for mild-to-moderate Alzheimer's disease (AD).</li>
<li>Shares of Oragenics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#NYSE">OGEN</a>) were down 45% to $0.59. Oragenics priced its $4.45 million public offering of 8,106,584 shares at $0.55 per share.</li>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) was down, falling 33% to $0.2482. The company announced it entered into a worldwide, exclusive royalty-bearing IP licensing agreement with PsyLabs.</li>
</ul>
Commodities In commodity news, oil traded down 1% to $69.68 while gold traded up 0.2% at $2,527.20.
Silver traded up 0.9% to $28.595 on Wednesday, while copper fell 0.3% to $4.0805.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.97%, Germany's DAX fell 0.83% and France's CAC 40 fell 0.98%. Spain's IBEX 35 Index fell 0.58%, while London's FTSE 100 fell 0.35%.
The S&amp;P Global UK services PMI climbed to 53.7 in August from 52.5 in the prior month. Producer prices in the Eurozone rose 0.8% month-over-month in July versus a revised 0.6% increase in June. The HCOB Eurozone composite PMI was revised lower to 51 in August versus a flash reading of 51.2.
Asia Pacific Markets
Asian markets closed lower on Wednesday, with Japan's Nikkei 225 falling 4.24%, Hong Kong's Hang Seng Index falling 1.10%, China's Shanghai Composite Index declining 0.67% and India's BSE Sensex falling 0.25%.
The HSBC India Composite PMI rose to 60.7 in August versus a flash reading of 60.5. Caixin China General Composite PMI came in unchanged at 51.2 in August.
Economics
The trade deficit in the U.S. increased to $78.8 billion in July, recording the biggest gap since June 2022, versus a gap of $73 billion in June.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40708182/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-7-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 7% Dividend Yields</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

ATHA

ATRA

DLTR

FFIE

OGEN

WISA

Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings

Psyence Biomedical Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares are trading lower by 28.6% to $0.25 during Wednesday&#8217;s session. The company earlier announced it entered into an exclusive licensing agreement with <a href="https://www.benzinga.com/pressreleases/24/09/g40704258/psyence-biomed-announces-worldwide-exclusive-licensing-agreement-with-psylabs-to-supply-nature-der">PsyLabs</a>, a company specializing in psychedelic pharmaceutical ingredients.
Under this agreement, PsyLabs will provide Psyence Biomed with pharmaceutical-grade, nature-derived psilocybin for use in clinical trials and potential commercialization. Psyence Biomed plans to focus initially on alcohol use disorder (AUD) in their clinical trials, with future development work extending into 2025. 
Additionally, they aim to begin a Phase IIb trial to assess psilocybin&#8217;s effectiveness in treating Adjustment Disorder in advanced cancer patients under palliative care.
Read Also: <a href="https://www.benzinga.com/news/24/09/40707836/nordstrom-stock-volatile-after-founding-family-offers-to-take-department-store-private">Nordstrom Stock Volatile After Founding Family Offers To Take Department Store Private</a> 
<h2 class="wp-block-heading">Should I Sell My PBM Stock?</h2>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Shares of Psyence Biomedical have lost 90.13% year to date. This compares to the average annual return of -66.93%, meaning the stock has underperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity. 
For analysis tools, charting data and access to exclusive stock news, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PBM has a 52-week high of $4.31 and a 52-week low of $0.21.

Psyence Biomedical (PBM) Stock Is Down 30%: What's Going On?

WIIM

Psyence Biomedical shares are trading lower. The company announced it entered into a worldwide, exclusive royalty-bearing IP licensing agreement with PsyLabs.

Psyence Biomedical Announced That The Company Has Entered Into A Worldwide, Exclusive Royalty-bearing Ip Licensing Agreement With PsyLabs

Psyence Biomedical Announces Registration Statement On Form F-1 For Up To $25M Equity Line of Credit With White Lion Capital, Declared Effective By SEC

Psyence Biomedical And Optimi Health Sign Sign Non-Binding Letter Of Intent To Advance Global Psilocybin Drug Development; Agreement Would Make Optimi Exclusive Supplier Of GMP Non-Synthetic Psilocybin Extract For Psyence's Initiatives

Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) ("Psyence Biomed" or the "Company") today announced that it has entered into a $25 million common stock purchase agreement (the "Purchase Agreement") with White Lion Capital, LLC, ("White Lion") a California-based institutional investor focused on high-growth, early-stage public companies.&nbsp; &nbsp; &nbsp;
Psyence Biomed will have the option, but not the obligation, to sell to White Lion up to $25.0 million in shares of common stock over a 24-month period subject to certain conditions, including a registration statement being filed and declared effective by the SEC.
The price to be paid by White Lion for any shares that Psyence Biomed requires White Lion to purchase will depend on the type of purchase notice that the Company delivers. For shares being issued pursuant to a Fixed Purchase Notice, the purchase price per share will be equal to 90% of the lowest VWAP of the common stock that occurs during the Fixed Purchase Valuation Period. For shares being issued pursuant to a Rapid Purchase Notice, the purchase price per share will be equal to the lowest traded price of the Common Stock on the Rapid Purchase Notice Date. There are no upper limits to the price White Lion may pay to purchase common stock from Psyence Biomed.

Financing

Psyence Biomed Enters Into $25M Common Stock Purchase Agreement With White Lion Capital

Shares of Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) fell sharply during Thursday's session after the company reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired <a href="https://www.benzinga.com/quote/EW/earnings">JenaValve and Endotronix</a>.
Edwards Lifesciences reported quarterly earnings of 70 cents per share which beat the analyst consensus estimate of 69 cents per share. The company reported quarterly sales of $1.632 billion which missed the analyst consensus estimate of $1.653 billion.
Edwards Lifesciences shares dipped 26.9% to $63.60 on Thursday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Predictive Oncology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) shares jumped 85% to $1.96 after the company entered biomarker discovery market after successful retrospective ovarian cancer study yields compelling results.</li>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) rose 65.4% to $0.6424 after the company announced the export of nature-derived psilocybin to Australia and said a trial is projected to be initiated shortly following receipt of drug product by trial sites.</li>
<li>Salarius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) jumped 60% to $3.4421.</li>
<li>Goosehead Insurance, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) rose 29.8% to $85.25 following upbeat second-quarter results.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares gained 28.2% to $64.64 after the company reported better-than-expected second-quarter EPS results.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) rose 27% to $0.5090.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) gained 25.4% to $0.2645 after gaining around 8% on Wednesday.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) rose 25.2% to $16.72. The company announced the successful completion of its first five commercial satellites.</li>
<li>Bally&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) gained 24.2% to $16.80. Bally&#8217;s entered into merger agreement with affiliates of Standard General L.P.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) climbed 18.3% to $341.39 following better-than-expected quarterly earnings.</li>
<li>The Shyft Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHYF#NASDAQ">SHYF</a>) gained 16.4% to $13.55 following upbeat earnings.</li>
<li>Carpenter Technology Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRS#NYSE">CRS</a>) climbed 16.3% to $141.59 after the company reported better-than-expected quarterly financial results.</li>
<li>Indivior PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) rose 15.4% to $12.56 after the company posted better-than-expected second-quarter results and announced an accelerated $100 million share repurchase program.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares climbed 15.4% to $0.3499.</li>
<li>RPC, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RES#NYSE">RES</a>) gained 15.1% to $6.64 following upbeat earnings.</li>
<li>ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) jumped 13.7% to $831.97 after the company reported better-than-expected second-quarter financial results.</li>
<li>Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) rose 13.1% to $69.09 after the company reported better-than-expected second-quarter financial results.</li>
<li>Helmerich &amp; Payne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) climbed 12.5% to $42.46 following third-quarter results.</li>
<li>BloomZ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) gained 12.2% to $2.75 after dipping 43% on Wednesday. BloomZ recently priced its IPO at $4.30 per share.</li>
<li>Valmont Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) gained 11.1% to $300.96 following upbeat earnings.</li>
<li>Plexus Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) rose 10.5% to $128.36 following upbeat earnings.</li>
<li>Knight-Swift Transportation Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) rose 10.1% to $53.92 following second-quarter results.</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) gained 9.6% to $565.64 after the company reported better-than-expected second-quarter adjusted EPS and sales.</li>
<li>Mr. Cooper Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NYSE">COOP</a>) rose 9.5% to $94.86 following second-quarter results.</li>
<li>Oceaneering International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OII#NYSE">OII</a>) gained 9.2% to $27.79 following strong sales.</li>
<li>RTX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) surged 8% to $113.24 following a second-quarter earnings beat.</li>
<li>J.B. Hunt Transport Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) gained 6.1% to $173.75.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) shares dipped 60% to $1.65. 2U announced a strategic agreement with debtholders to eliminate half of debt and infuse $110 million in new capital.</li>
<li>EZFill Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZFL#NASDAQ">EZFL</a>) tumbled 40.3% to $3.73.</li>
<li>Kindly MD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) fell 37.5% to $2.04 after the company submitted comment to the Department of Justice regarding cannabis rescheduling.</li>
<li>Cheetah Net Supply Chain Service Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) dipped 34% to $0.3185. Cheetah Net Supply Chain Service announced pricing of $1.49 million follow-on public offering.</li>
<li>MaxLinear, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NYSE">MXL</a>) shares fell 30.7% to $15.45 after the company reported worse-than-expected second-quarter financial results.</li>
<li>Sol-Gel Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLGL#NASDAQ">SLGL</a>) dipped 30% to $0.4750. Sol-Gel announced the signing of six exclusive license agreements to commercialize TWYNEO&#xAE; and EPSOLAY&#xAE; in Europe and South Africa.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) fell 29.7% to $9.49 after declining 10% on Wednesday.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) fell 27% to $0.1159.</li>
<li>Orion Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) declined 21.9% to $8.62 after the company reported worse-than-expected second-quarter financial results.</li>
<li>Ostin Technology Group Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares declined 20.3% to $0.35 after gaining around 19% on Wednesday.</li>
<li>Ribbon Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) tumbled 19.2% to $3.1450 after the company reported worse-than-expected quarterly revenue.</li>
<li>Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) shares fell 16.6% to $11.40 following a second-quarter earnings miss.</li>
<li>Hoth Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) fell 15.1% to $0.9103. Hoth Therapeutics shares gained around 11% on Wednesday after the company signed an agreement with LTS Therapy Systems to develop and manufacture the HT-ALZ oral film prototype for Alzheimer&#8217;s disease.</li>
<li>Garrett Motion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>) declined 13.8% to $7.86 after the company reported worse-than-expected quarterly financial results and lowered its FY24 guidance.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) shares fell 13.4% to $0.0396 after jumping over 75% on Wednesday.</li>
<li>Kaiser Aluminum Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALU#NASDAQ">KALU</a>) declined 13.3% to $79.76 after the company reported worse-than-expected quarterly financial results.</li>
<li>Hut 8 Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NYSE">HUT</a>) declined 12.8% to $15.71.</li>
<li>LKQ Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) fell 12.1% to $39.10 after the company reported worse-than-expected quarterly adjusted EPS and sales. Additionally, the company lowered its FY24 adjusted EPS outlook.</li>
<li>STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) shares fell 12% to $34.81 after the company reported a second-quarter EPS miss and issued soft third-quarter guidance.</li>
<li>Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) dipped 9.7% to $129.30 following soft third-quarter guidance.</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) fell 9.5% to $292.91 after the company reported a quarterly earnings miss and cut its guidance.</li>
<li>FormFactor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORM#NASDAQ">FORM</a>) fell 8.2% to $52.26.</li>
<li>Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) tumbled 8.2% to $249.52 after Citigroup downgraded the stock from a Buy to a Neutral and lowered its price target from $415 to $300.</li>
<li>Robert Half Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHI#NYSE">RHI</a>) declined 7% to $60.32 after the company reported worse-than-expected second-quarter financial results.</li>
<li>Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) fell 6.8% to $18.27 following H1 results.</li>
<li>QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) shares fell 6.2% to $7.01 after the company reported worse-than-expected EPS results.</li>
<li>Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) declined 4.1% to $204.82 after the company lowered FY24 EPS guidance.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39961297/this-lululemon-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-thursday">This Lululemon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday</a></li>
</ul>

ASTS

BALY

BLMZ

CERO

COOP

CTNT

EZFL

FORM

GSHD

HOTH

INDV

JBHT

KALU

KDLY

LULU

PEGA

PLXS

POAI

RBBN

SHYF

SLGL

SLNA

SLRX

STLA

TIVC

TWOU

VKTX

Why Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Psyence Biomedical Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares are trading higher by 48% to $0.58 during Thursday&#8217;s session after the company announced the export of nature-derived psilocybin to Australia and said a trial is projected to be initiated shortly following receipt of <a href="https://www.benzinga.com/pressreleases/24/07/g39942043/psyence-biomed-announces-export-of-nature-derived-psilocybin-to-australia-and-provides-update-on-u">drug product by trial sites</a>.
Psyence says the company has partnered with Fluence and iNGENū CRO Pty Ltd to support the study, which will involve 84 patients and compare two doses of psilocybin (10mg and 25mg) with a low-dose placebo (1mg) alongside psychotherapy. 
The company is preparing to start the trial soon following the successful export of the drug candidate, PEX010, and is focusing on patient enrollment.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39955365/bitcoin-tumbles-3-ethereum-plunges-below-3-200-what-is-going-on-with-etfs">Bitcoin Tumbles 3%, Ethereum Plunges Below $3,200: What Is Going On With ETFs?</a>
<h2 class="wp-block-heading">How To Buy PBM Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Psyence Biomedical&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PBM has a 52-week high of $4.31 and a 52-week low of $0.27.

Why Psyence Biomedical (PBM) Stock Is Skyrocketing

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 1% on Thursday.
The Dow traded up 1.36% to 40,396.01 while the NASDAQ rose 1.06% to 17,526.08. The S&amp;P 500 also rose, gaining, 1.09% to 5,486.47.
Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39957788/jim-cramer-this-tech-stock-is-absolutely-terrific-but-jumia-its-not-making-a-lot-of-mone"> Cramer: This Tech Stock Is &#8216;Absolutely Terrific,&#8217; But Jumia? It&#8217;s Not Making A Lot Of Money</a>
Leading and Lagging Sectors Industrials shares jumped by 2.2% on Wednesday.
In trading on Wednesday, utilities shares fell by 0.2%.
Top Headline
American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) reported mixed second-quarter 2024 financial results and lowered its 2024 EPS outlook.
The airline reported second quarter total operating revenue growth of 2% year-over-year to $14.334 billion, missing the consensus of $14.36 billion. The company reported an adjusted EPS of $1.09, down from $1.92 a year ago and above the consensus $1.05.
For 2024, American now expects an adjusted EPS of $0.70 to $1.30 (prior $2.25 to $3.25) versus the consensus of $1.81. It expects 2024 operating margin of 3.5% to 5.5%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Predictive Oncology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) shares shot up 67% to $1.7896 after the company entered biomarker discovery market after successful retrospective ovarian cancer study yields compelling results.</li>
<li>Shares of Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) got a boost, surging 52% to $0.5888 after the company announced the export of nature-derived psilocybin to Australia and said a trial is projected to be initiated shortly following receipt of drug product by trial sites.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares were also up, gaining 34% to $67.50 after the company reported better-than-expected second-quarter EPS results. The company also announced the advancement of VK2735 to Phase 3.</li>
</ul>
Equities Trading DOWN
<ul>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) shares dropped 61% to $1.6117 after the company filed for Chapter 11 bankruptcy to facilitate a Restructuring Support Agreement.</li>
<li>Shares of Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) were down 27% to $63.58 after the company reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix.</li>
<li>Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) was down, falling 16% to $11.48 after the company missed analyst EPS estimates for the 2024 fiscal year second quarter.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/07/39958830/top-3-defensive-stocks-that-are-ticking-portfolio-bombs">Top 3 Defensive Stocks That Are Ticking Portfolio Bombs</a>
Commodities In commodity news, oil traded up 0.7% to $78.13 while gold traded down 2.3% at $2,360.50.
Silver traded down 4.3% to $28.050 on Thursday, while copper rose 0.4% to $4.1245.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.72%, Germany's DAX fell 0.48% and France's CAC 40 fell 1.15%. Spain's IBEX 35 Index fell 0.58%, while London's FTSE 100 rose 0.40%.
Bank lending to households in the Eurozone rose by 0.3% year-over-year to €6.879 trillion in June. The Ifo Business Climate indicator for Germany fell for a third straight month to a reading of 87 in July from 88.6 in June. The manufacturing climate indicator in France declined to 95.5 in July from 98.9 in the prior month.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei 225 falling 3.28%, Hong Kong's Hang Seng Index falling 1.77%, China's Shanghai Composite Index declining 0.52% and India's S&amp;P BSE Sensex declining 0.14%.
Imports to Hong Kong climbed 9% year-over-year to $429.2 billion, while exports from Hong Kong gained 10.7% to $373.5 billion in June. The People's Bank of China cut its one-year policy loan rate.
Economics
<ul>
<li>U.S. initial jobless claims declined by 10,000 to 235,000 in the week ending July 20, compared to market estimates of 238,000.</li>
<li>U.S. durable goods orders fell by 6.6% month-over-month in June.</li>
<li>The US economy grew by an annualized 2.8% in the second quarter, up from 1.4% in the prior quarter, and higher than expectations of 2%.</li>
<li>The EIA said US natural-gas stocks increased 22 billion cubic feet during the week ended July 19, higher than market estimates of a 15 billion cubic feet gain.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39958828/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 6% Dividend Yields</a> </li>
</ul>

Nasdaq Gains 1%; American Airlines Cuts Earnings Forecast

Generation PMCA Q2 2024 Quarterly

Psyence Biomedical (PBM) has released an update. Psyence Biomedical Ltd. has released an investor presentation highlighting its focus on developing...

Psyence Biomedical Shares Clinical Ambitions

Psyence Biomedical (PBM) has released an update. Psyence Biomedical has struck a pivotal licensing agreement with PSYUK, granting them exclusive ri...

Psyence Biomedical Secures Psilocybin Licensing Deal

Psyence Biomedical to acquire drug developer Clairvoyant

Psyence Biomedical receives delisting determination from Nasdaq

Psyence Biomedical (PBM) has released an update. Psyence Biomedical Ltd., a company developing psilocybin-based medicines, has been notified by Nas...

Psyence Biomedical Faces Nasdaq Delisting Risk

Psyence Biomedical (PBM) has released an update. Psyence Group Inc. has agreed to sell a portion of its shares in Psyence Labs Ltd. to Psyence Biom...

Psyence Group Sells Stake to Psyence Biomedical

Psyence Biomedical files to sell 10.9M common shares for holders.

Psyence Biomedical files to sell 10.9M common shares for holders

Psyence Biomedical to not proceed with Clairvoyant acquisition

AAPL

ARKAF

ARKAY

DGEAF

EMLAF

LVMHF

LVMUY

MSFT

NVDA

PBMWW

SBUX

SIRI

UNLYF

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC

Psyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs)

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

Health Care

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Comments

Psyence Biomedical

Noticias

Últimas noticias sobre Psyence Biomedical (NASDAQ:PBM) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL